Caris Life Sciences, Inc. (CAI) Stock Price Quote, News &…

Summary

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

Website

www.carislifesciences.com

Location

Irving, TX, US

Phone866 771 8946

Employees1,846

CEODavid Dean Halbert

Sector

Health Care

Industry

Health Care Equipment & Supplies

IPO DateJun 18, 2025

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… chnologies. CNSide Platform Companies offering or developing cerebrospinal fluid-based or blood-based tumor cell detection, molecular profiling, or other oncology diagnostic technologies for patients with primary or metastatic CNS cancers include Belay Diagnostics, Lucence, Menarini Silicon Biosystems, Caris Life Sciences, Genomic Testing Cooperative, NeoGenomics, Quest Diagnostics, Labcorp, BillionToOne, Predicine, FYR Diagnostics, and others.
CERENOME, INC.Caris Life Sciences, Inc.·10-Q - Quarterly report Q3·Q3 26·05:06PM
Some of our present or potential competitors, including Adela, Inc., Caris Life Sciences, Inc., DELFI Diagnostics, Inc., Exact Sciences Corporation which was acquired by Abbott Laboratories, Inc., in March 2026, Foresight Diagnostics Inc. (“Foresight”), which was acquired by Natera in December 2025, Foundation Medicine, Inc., GRAIL, Inc., Guardant Health, Inc., Haystack Oncology, Inc., which was acquired by Quest Diagnostics Incorporated in June …
Personalis, Inc.Caris Life Sciences, Inc.·10-Q - Quarterly report Q3·Q3 26·4 Nov
… ions, primary and secondary public equity offerings, bank lending, bond offerings and other transactions. He started his career at PricewaterhouseCoopers LLP. Mr. Gilliam currently sits on the board of directors of Caris Life Sciences, where he also serves on the audit and compensation committees. Mr. Gilliam has a B.S. in accounting from the Kelly School of Business at Indiana University. The Company believes Dr. Satpathy is qualified to serve …
10x Genomics, Inc.Caris Life Sciences, Inc.·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q4 26·2 Nov
… unology-focused precision-medicine and diagnostics companies, including Aqtual, Prometheus Laboratories, Immunai, and CytoReason, as well as broader molecular-diagnostics and precision-medicine companies, including Caris Life Sciences, Foundation Medicine, an affiliate of Roche, Tempus AI, Labcorp, QIAGEN, Myriad Genetics and NeoGenomics. We also compete with biopharmaceutical companies that develop biomarker and companion-diagnostic capabilities …
Chemomab Therapeutics Ltd.Caris Life Sciences, Inc.·DEFM14A - Definitive proxy statement (merger)·Q4 26·30 Oct
… unology-focused precision-medicine and diagnostics companies, including Aqtual, Prometheus Laboratories, Immunai, and CytoReason, as well as broader molecular-diagnostics and precision-medicine companies, including Caris Life Sciences, Foundation Medicine, an affiliate of Roche, Tempus AI, Labcorp, QIAGEN, Myriad Genetics and NeoGenomics. We also compete with biopharmaceutical companies that develop biomarker and companion-diagnostic capabilities …
Snowdrift Parent CorpCaris Life Sciences, Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·30 Oct
… unology-focused precision-medicine and diagnostics companies, including Aqtual, Prometheus Laboratories, Immunai, and CytoReason, as well as broader molecular-diagnostics and precision-medicine companies, including Caris Life Sciences, Foundation Medicine (an affiliate of Roche), Tempus AI, Labcorp, QIAGEN, Myriad Genetics and NeoGenomics. We also compete with biopharmaceutical companies that develop biomarker and companion-diagnostic capabilitie …
Snowdrift Parent CorpCaris Life Sciences, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·29 Oct

Key Stats

Trading

Px/Chg 1D$28.30 / -0.18%

Prev Close$25.07

% of 52Wk H67.46%

Avg Volume2.65M

Beta1.42

Mkt Cap8.00B

FD Mkt Cap7.02B

Float

Shrs Out/Float282.68M / 11.29M

Short Float1.26%

Days to Cover4.33

Stock Repurchased$0.00

Current Valuation

EV7.61B

EV/EBITDA72.83

EV/Sales8.39

P/B13.48

P/S8.82

FCF Yield0.28%

ROE-0.09%

ROA-0.04%

Current Ratio7.05

Estimates

P/E235.41

Est P/E0.00

Est EPS-0.02

Est PEG0.00

Valuation

Metric	5Yr Avg	May '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	-7,898.36	404.77	-16,201.48
Price / Sales	75.74	113.26	38.22
Price / Book Value	35.69	57.46	13.92
Price / Free Cash Flow	601.25	835.82	366.68
ENTERPRISE VALUE METRICS
Enterprise Value	20,313.7	32,754.8	7,872.6
Enterprise Value / Sales	74.13	111.83	36.42
Enterprise Value / EBITDA	548.22	335.59	760.86
Enterprise Value / EBIT	920.74	351.02	1,490.45

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Dec '20	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	28.9%	294.0	258.5	306.1	412.3	812.0
Gross Income	30.8%	184.2	80.0	89.3	178.8	539.2
EBITDA	-54%	254.5	-245.9	-260.8	-183.0	11.4
EBIT	—	143.8	-294.1	-309.8	-231.9	-11.2
Net Income	—	27.7	-320.8	-341.4	-281.9	-538.0
EPS (Diluted)	—	1.55	-1.57	-1.82	-2.70	-1.90
BALANCE SHEET
Cash & ST Inv	56.7%	132.5	409.6	121.6	66.2	800.1
Total Assets	-19%	2,612.6	717.4	412.9	343.7	1,125.7
Total Liabilities	-26.8%	1,910.4	2,419.5	2,557.9	2,842.6	548.4
Total Shareholder Equity	-4.8%	702.2	-1,702.1	-2,145.0	-2,498.8	577.3
CASH FLOW
Net Operating Cash Flow	-26%	277.0	-285.7	-276.1	-245.2	83.2
Cap Ex	-47.8%	-219.5	-42.3	-22.3	-8.4	-16.3
Free Cash Flow	3.8%	57.6	-328.0	-298.4	-253.6	66.9

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		22.97
Basic Shares		282.68
Market Cap		6,493.2
Diluted Shares		295.14
Fully Diluted Shares Outstanding		295.14
Fully Diluted Market Cap		6,779.4
+Consolidated Debt		69.8
−In-the-Money Convertible Debt		—
+Capital Leases		69.8
+Operating Leases		—
−Cash & Equivalents		-665.3
−Short-term Investments		-102.1
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		5,897.6

Related companies